GC

IR Information

GREAT
COMPANY

Towards Corporate Value of 50 Trillion
in 2030

Stock Status

As a global leader in the health industry,
we are increasing corporate value
across various business areas

Total Number of Shares [as of the end of 2022]Unit: Number of shares

Total Number of Shares1
Type	Common stock	Preferred stock	Total
Total issued	47,028,210	2,514,860	49,543,070
Treasury stock	2,094,020	2,047,319	4,141,339
In circulation	44,934,190	467,541	45,401,731

Total Number of Shares 2
Type	Stock Type	FY2022	FY2021	FY2020
Face price per share (KRW)		500	500	500
(Consolidated) net income (in KRW million)		32,823	55,270	170,960
(Separate) net income (in KRW million)		16,120	35,663	50,376
(Consolidated) net income per share (KRW)*		727	1,222	3,793
Total payout in cash (in KRW million)		13,622	18,162	22,702
(Consolidated) propensity to cash payout (%)		41.5	32.9	13.3
Cash dividend yield ratio (%)	Common stock	1.8	1.5	1.4
Cash dividend yield ratio (%)	Preferred stock	-	-	-
Weekly Cash dividend ratio (KRW)	Common stock	300	400	500
Weekly Cash dividend ratio (KRW)	Preferred stock	305	405	505

*This amount includes discontinued operations.

Summary Consolidated Income Statement Unit: KRW million

Summary Consolidated Income Statement
Type	2022	2021	2020
Sales	2,079,560	1,840,559	1,719,326
Operating Profit	71,160	86,244	70,732
Net Income Before Income Tax Expenses	29,629	180,013	107,919
Net Income	58,897	127,658	179,995
Total Comprehensive Income	80,610	155,208	184,695

Summary Consolidated Statement of Financial Position Unit: KRW million

신용등급 ※ 회사채 신용평가는 매년 1회 정기평가를 받고 있습니다

신용등급 표
구분	한국기업평가	신용등급	A+ (2020년)
구분	NICE 신용평가	신용등급	AA- (2020년)